eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2021-09-30 14 3 1561 1565 10.13005/bpj/2258 40615 article Mohamed N. Ibrahim 1 Clinical Laboratories department, College of Applied Medical Sciences, Jouf University, Qurayat, Saudi Arabia Microbiology department, Faculty of Science, Ain Shams University, Egypt One of the biggest infectious diseases for humans in modern history is the COVID-19 pandemic. The disease mechanisms of human viral infections have been modified by virus-virus interaction. This study was carried out to detect the seroprevalence of CMV in COVID-19 patients. A total of 105 cases (58 females and 47 males) with an age range of 17-65 years (mean age 39.52±11.02 years) were included in this study. HCMV-IgG and IgM were determined in subjects' cases. Sixty-five out of 105 (62%) were positive for SARS-CoV-2, while 40 (38%) had negative SARS-CoV-2. Forty-seven (72.3%) and 11 (16.9%) cases out of 65 SARS-CoV-2 positive patients were positive for CMV-IgG and IgM antibodies, respectively. No significant differences were noted between females and males in terms of seroprevalence rates. A high rate of positive CMV-IgG was observed among 40-64 years COVID-19 patients. It is concluded that the seroprevalence of CMV antibodies amongst COVID-19 cases is high in relation to findings in cases without SARSCoV-2. https://biomedpharmajournal.org/vol14no3/seroprevalence-of-cytomegalovirus-antibodies-among-covid-19-patients/ COVID-19 Cytomegalovirus CMV-IgG CMV- IgM  SARS-CoV-2